Inomax
Sickle Cell Disease
Assistance Publique - Hôpitaux de ParisPhase 2/3Dormant
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 58/ 100
- Competitive Position
- 65/ 100
Competitive context
122 Active assets in the Sickle Cell Disease cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Hydroxyurea St. Jude Children's Research Hospital | Phase 4 | BB |
FILGRASTIM St. Jude Children's Research Hospital | Phase 4 | BB |
Crizanlizumab Novartis Pharmaceuticals | Phase 4 | BB |
NEPENTHE Oman Medical Speciality Board | Phase 4 | BB |
ARG Tanta University | Phase 3 | BB |
View all 50 →
Same molecule, other indications
Inomax is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →